At the same time, accumulating evidence has elucidated that the PI3K–Akt signaling pathway is highly activated (Guo et al., 2015; Hao et al., 2019) and is a validated therapeutic target in RCC (Lin et al., 2014). Here, AKT1 is linked to renal cell carcinoma.